Mirati Therapeutics (MRTX) Announces European Commission Approves KRAZATI as Targeted Treatment Option for Patients with Advanced NSCLC with a KRASG12C Mutation

Mirati Therapeutics (MRTX) Announces European Commission Approves KRAZATI as Targeted Treatment Option for Patients with Advanced NSCLC with a KRASG12C Mutation

streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.